Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1995-05-30
1999-06-15
Scheiner, Laurie
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
435236, 4351723, 435 914, 4241881, 4241991, 4242081, C07H 2104
Patent
active
059123389
ABSTRACT:
This invention is directed toward nucleic acids encoding self-assembled, non-infectious, non-replicating, immunogenic retrovirus-like particles comprising modified HIV-1 genomes devoid of long terminal repeats and containing nucleotide sequences encoding chimeric envelope glycoproteins. Retrovirus-like particles containing chimeric envelope glycoproteins were expressed in mammalian cells by using inducible promoters. One preferred embodiment discloses the engineering of a series of expression vectors in which a synthetic oligomer encoding gp120 residues 306 to 328 (amino acids YNKRKRIHIGP GRAFYTTKNIIG) from the V3 loop of the MN viral isolate was inserted at various positions within the endogenous HIV-1.sub.LAI env gene. Expression studies revealed that insertion of the heterologous V3(MN) loop segment resulted in the secretion of fully assembled HIV-like particles containing chimeric LAI/MN envelope glycoproteins. Both V3 loop epitopes were recognized by loop-specific neutralizing antibodies. Immunization with HIV-like particles containing chimeric envelope proteins induced specific antibody responses against both the autologous and heterologous V3 loop epitopes, including cross-neutralizing antibodies against the HIV-1.sub.LAI and HIV-1.sub.MN isolates.
REFERENCES:
patent: 5439809 (1995-08-01), Haynes et al.
Tucker et al., 1991, Virol. 185:710-720.
Rovinski et al., 1992, J. Virol. 66:4003-4012.
Haynes et al., 1991, AIDS Res. Human Retro. 7:17-27.
Ohno et al., 1991, Proc. Natl. Acad. Sci. USA 88:10726-10729.
Ivanoff et al., 1991, AIDS Res. Human Retro. 7:595-603.
Boswell et al., 1988, "Sequence comparison and alignment: the measurement and interpretation of sequence similarity", in Computational Molecular Biology, Lesk, Oxford University Press, New York, New York, pp. 161-178.
Thomas J. Palker et al The Journal of Immunology, vol. 142, No. 3, Feb. 1, 1989.
Haseltine, W.A., "Replication and Pathogenesis of the AIDS Virus", 1988, Jour. of Acq. Immun. Def. Synd., 1:217-240.
Varmus, H. "Retroviruses", 1988, Science 240:1427-1435.
Aldovini, A. and R. Young, 1990. Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus. J. Virol. 64:1920-1926.
Allan, J.S. et al. 1985. Major Glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228:1091-1094.
Arthur, L.O. et al, 1989. Challenge of chimpanzees (Pantroglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120. J. Virol. 63:5046-5053.
Arthur, L.O. et al, 1987. Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc. Natl. Acad. Sci. USA 84:8583-8587.
Barre-Sinoussi, F. et al; 1983. Isolation of a T-lymphocyte retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 230:868-871.
Berman, P.W., et al, 1990. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotien gp120 but not gp160. Nature (London) 345:622-625.
Bolognesi, D.P. 1989. HIV antibodies and vaccine design AIDS 3 (suppl. 1):S111-S118.
Chanh, T.C. et al, 1986. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J.5:3065-3071.
Cordonnier, A. et al, 1989. Effects of mutations in hyperconserved regions of the extracellular glycoprotein of human immunodeficiency virus type 1 on receptor binding. J. Virol. 63:4464-4468.
Dalgleish, A.G. et al, 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (London) 312:763-766.
Desrosiers, R.C., et al, 1989. Vaccine protection against simian immunodeficiency virus infection. Proc. Natl. Acad. Sci. USA 86:6353-6357.
DiMarzo-Veronese, F., et al, 1985. Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science 229:1402-1405.
Dowbenko, D., et al, 1988. Epitope mapping of the human immunodeficiecny virus type 1 gp120 with monoclonal antibodies. J. Virol.62:4703-4711.
Durda, P.J., et al, 1990. HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide. AIDS Res. Hum. Retroviruses 6:1115-1123.
Earl, P.L. et al. 1991. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressedby recombinant vaccinia viruses. J. Virol. 65:31-41.
Earl, P.L. et al, 1989. Isolate-and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques. AIDS Res. Hum. Retroviruses 5:23-32.
Gallo, R.C., et al. 1984. Frequent detection and isolation of cytopathic 9HTLV-III) from patients with AIDS and at risk for AIDS. Science 224:500-503.
Gardner, M.V. 1990. Vaccination against SIV infection and disease. AIDS Res. and Hum. Retroviruses 6:835-846.
Gheysen, D., et al, 1989. Assembly and release of HIV-1 precursor pr55gag virus-like particles from recombinant baculovirius-infected cells. Cell 59:103-112.
Gibbs, C.J. et al 1991. Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees. Proc. Natl. Acad. Sci. USA 88:3348-3352.
Girard, M., et al. 1991. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88:542-546.
Gorny, M.K, et al. 1991. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA 88:3238-3242.
Goudsmit, J. et al. 1988. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl. Acad. Sci. USA 85:4478-4482.
Haffar, O.K., et al 1991. HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles. Virology 183:487-495.
Haffar, O., 1990. Human immunodeficiency virus-like, non-replicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J. Virol. 64:2653-2659.
Haigwood, N.L., et al. 1992. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J. Virol. 66:172-182.
Haynes, J.R., et al 1991. Production of immunogenic HIV-1 virus-like particles in stably engineered monkey cell lines. AIDS Res. Hum. Retroviruses 7:17-27.
Helseth, E, et al. 1991. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J. Virol. 65:2119-2123.
Ho, D.D., et al, 1988. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science 239:1021-1023.
Hu, S.L. et al, 1991. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologus gp160. AIDS Res. Hum. Retroviruses. 7:615-620.
Jahaverian, K, et al, 1990. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 250:1590-1593.
Karacostas, V., et al 1989. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc. Natl. Acad. Sci. USA 86:8964-8967.
Kennedy, R.C. et al, 1988. Perspectives on developing anti-idiotype-based vaccines for controlling HIV infection. AIDS 2(Suppl. 1):S119-S127.
Klatzman, D., et al 1984. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (London) 312:767-768.
Kowalski, M, et al 1987. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 237:1351-1355.
Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 227:680-685.
Lasky, L.A. et al, 1987. Delineation of a region of th
Cao Shi Xian
Haynes Joel
Klein Michel Henri
Rovinski Benjamin
Parkin Jeffrey S.
Rovinski Benjamin
Scheiner Laurie
LandOfFree
Nucleic acids encoding self-assembled, non-infectious, non-repli does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding self-assembled, non-infectious, non-repli, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding self-assembled, non-infectious, non-repli will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-403404